High-dose therapy for amyloidosis: the end of the beginning?
- 15 May 2004
- journal article
- Published by American Society of Hematology in Blood
- Vol. 103 (10) , 3612-3613
- https://doi.org/10.1182/blood-2004-02-0732
Abstract
No abstract availableKeywords
This publication has 3 references indexed in Scilit:
- High-Dose Melphalan and Autologous Stem-Cell Transplantation in Patients with AL Amyloidosis: An 8-Year StudyAnnals of Internal Medicine, 2004
- High-dose intravenous melphalan and autologous stem cell transplantation as initial therapy or following two cycles of oral chemotherapy for the treatment of AL amyloidosis: results of a prospective randomized trialBone Marrow Transplantation, 2003
- Eligibility for Hematopoietic Stem-Cell Transplantation for Primary Systemic Amyloidosis Is a Favorable Prognostic Factor for SurvivalJournal of Clinical Oncology, 2001